Prognostic impact of trisomies of chromosomes 10, 17, and 5 among children with acute lymphoblastic leukemia and high hyperdiploidy (>50 chromosomes)

被引:123
作者
Heerema, NA
Sather, HN
Sensel, MG
Zhang, T
Hutchinson, RJ
Nachman, JB
Lange, BJ
Steinherz, PG
Bostrom, BC
Reaman, GH
Gaynon, PS
Uckun, FM
机构
[1] Childrens Canc Grp, Grp Operat Ctr, Arcadia, CA 91066 USA
[2] Hughes Inst, Dept Genet, St Paul, MN USA
[3] Childrens Canc Grp, Acute Lymphoblast Leukemia Biol Reference Lab, St Paul, MN USA
[4] Childrens Hlth Care, Dept Hematol Oncol, Minneapolis, MN USA
[5] Univ So Calif, Dept Prevent Med, Los Angeles, CA 90089 USA
[6] Childrens Hosp Los Angeles, Dept Pediat Hematol Oncol, Los Angeles, CA 90027 USA
[7] Univ Michigan, Dept Pediat Hematol Oncol, Ann Arbor, MI 48109 USA
[8] Univ Chicago, Dept Pediat Hematol Oncol, Chicago, IL 60637 USA
[9] Childrens Hosp, Div Oncol, Philadelphia, PA 19104 USA
[10] Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10021 USA
[11] George Washington Univ, Sch Med, Washington, DC USA
[12] Childrens Natl Med Ctr, Washington, DC 20010 USA
关键词
D O I
10.1200/JCO.2000.18.9.1876
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Children with acute lymphoblastic leukemia (ALL) and high hyperdiploidy (> 50 chromosomes) have improved outcome compared with other ALL patients. We sought to identify cytogenetic features that would predict differences in outcome within this low-risk subset of ALL patients. Materials and Methods: High-hyperdiploid ALL patients (N = 480) were enrolled between 1988 and 1995 on Children's Cancer Group (CCG) trials. Karyotypes were determined by conventional banding. Treatment outcome was analyzed by life-table methods. Results: Patients with 54 to 58 chromosomes had better outcome than patients with 51 to 53 or 59 to 68 chromosomes (P = .0002). Patients with a trisomy of chromosome 10 (P < .0001), chromosome 17 (P = .0002), or chromosome 18 (P = .004) had significantly improved outcome compared with their counterparts who lacked the given trisomy. Patients with a trisomy of chromosome 5 had worse outcome than patients lacking this trisomy (P = .02). Patients with trisomies of both chromosomes 10 and 17 had better outcome than those with ct trisomy of chromosome 10 (P = .09), a trisomy of chromosome 17 (P = .01), or neither trisomy (P < .0001). Multivariate analysis indicated that trisomy of chromosome 10 (P = .001) was the most significant prognostic factor for high-hyperdiploid patients, yet trisomy of chromosome 17 (P =.02) or chromosome 5 (P = .01) and modal chromosome number (P = .02) also had significant multivariate effects. Conclusion: Trisomy of chromosomes 10 and 17 as well as modal chromosome number 54 to 58 identify subgroups of patients with high-hyperdiploid ALL who have a better outcome than high-hyperdiploid patients who lack these cytogenetic features. Trisomy of chromosome 5 confers poorer outcome among high-hyperdiploid patients. (C) 2000 by American Society of Clinical Oncology.
引用
收藏
页码:1876 / 1887
页数:12
相关论文
共 53 条
[1]  
[Anonymous], 1993, Leukemia, V7, P10
[2]   Reduced folate carrier expression in acute lymphoblastic leukemia: A mechanism for ploidy but not lineage differences in methotrexate accumulation [J].
Belkov, VM ;
Krynetski, EY ;
Schuetz, JD ;
Yanishevski, Y ;
Masson, E ;
Mathew, S ;
Raimondi, S ;
Pui, CH ;
Relling, MV ;
Evans, WE .
BLOOD, 1999, 93 (05) :1643-1650
[3]   6-YEAR FOLLOW-UP OF THE CLINICAL-SIGNIFICANCE OF KARYOTYPE IN ACUTE LYMPHOBLASTIC-LEUKEMIA [J].
BLOOMFIELD, CD ;
SECKERWALKER, LM ;
GOLDMAN, AI ;
VANDENBERGHE, H ;
DELACHAPELLE, A ;
RUUTU, T ;
ALIMENA, G ;
GARSON, OM ;
GOLOMB, HM ;
ROWLEY, JD ;
KANEKO, Y ;
WHANGPENG, J ;
PRIGOGINA, E ;
PHILIP, P ;
SANDBERG, AA ;
LAWLER, SD ;
MITELMAN, F .
CANCER GENETICS AND CYTOGENETICS, 1989, 40 (02) :171-185
[4]  
BLOOMFIELD CD, 1983, CANCER RES, V43, P868
[5]  
BOSTROM B, 1998, P AN M AM SOC CLIN, V17, P527
[6]   Cytogenetics and prognosis in childhood lymphoblastic leukaemia: results of MRC UKALL X [J].
Chessells, JM ;
Swansbury, GJ ;
Reeves, B ;
Bailey, CC ;
Richards, SM .
BRITISH JOURNAL OF HAEMATOLOGY, 1997, 99 (01) :93-100
[7]   INTENSIFICATION OF TREATMENT AND SURVIVAL IN ALL CHILDREN WITH LYMPHOBLASTIC-LEUKEMIA - RESULTS OF UK MEDICAL-RESEARCH-COUNCIL TRIAL UKALL-X [J].
CHESSELLS, JM ;
BAILEY, C ;
RICHARDS, SM ;
EDEN, OB ;
BARBOR, PRH ;
BARRETT, A ;
BARTON, C ;
BROADBENT, V ;
DEMPSEY, SI ;
DURRANT, J ;
EMERSON, P ;
EVANS, DIK ;
FENNELLY, JJ ;
GALTON, DAG ;
GIBSON, B ;
GRAY, R ;
HANN, IM ;
HARDISTY, RM ;
HILL, FGH ;
KERNAHAN, J ;
KING, DJ ;
LILLEYMAN, JS ;
MANN, J ;
MARTIN, J ;
MCELWAIN, TJ ;
MELLOR, ST ;
JONES, PHM ;
OAKHILL, A ;
PETO, J ;
RADFORD, M ;
REES, JKH ;
STEVENS, RF ;
SUMMERFIELD, GP ;
THOMPSON, EN .
LANCET, 1995, 345 (8943) :143-148
[8]  
CHU E, 1996, CANC CHEMOTHERAPY BI
[9]   4-AGENT INDUCTION AND INTENSIVE ASPARAGINASE THERAPY FOR TREATMENT OF CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA [J].
CLAVELL, LA ;
GELBER, RD ;
COHEN, HJ ;
HITCHCOCKBRYAN, S ;
CASSADY, JR ;
TARBELL, NJ ;
BLATTNER, SR ;
TANTRAVAHI, R ;
LEAVITT, P ;
SALLAN, SE .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 315 (11) :657-663
[10]  
COX DR, 1972, J R STAT SOC B, V34, P187